Cadrenal Therapeutics, Inc.
CVKD
$1.19
-$0.01-0.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.63M | 1.74M | 2.40M | 2.04M | 2.66M |
| Depreciation & Amortization | 500.00 | 600.00 | 600.00 | 400.00 | 400.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.34M | 2.51M | 3.07M | 2.73M | 3.73M |
| Operating Income | -3.34M | -2.51M | -3.07M | -2.73M | -3.73M |
| Income Before Tax | -3.32M | -2.50M | -3.04M | -2.69M | -3.67M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.32M | -2.50M | -3.04M | -2.69M | -3.67M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.32M | -2.50M | -3.04M | -2.69M | -3.67M |
| EBIT | -3.34M | -2.51M | -3.07M | -2.73M | -3.73M |
| EBITDA | -3.34M | -2.51M | -3.06M | -2.73M | -3.73M |
| EPS Basic | -1.14 | -1.04 | -1.43 | -1.31 | -1.87 |
| Normalized Basic EPS | -0.71 | -0.65 | -0.89 | -0.82 | -1.17 |
| EPS Diluted | -1.14 | -1.04 | -1.43 | -1.31 | -1.87 |
| Normalized Diluted EPS | -0.71 | -0.65 | -0.89 | -0.82 | -1.17 |
| Average Basic Shares Outstanding | 2.91M | 2.41M | 2.12M | 2.04M | 1.96M |
| Average Diluted Shares Outstanding | 2.91M | 2.41M | 2.12M | 2.04M | 1.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |